323 related articles for article (PubMed ID: 27546298)
1. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.
Burke MJ; Rheingold SR
Leuk Lymphoma; 2017 Mar; 58(3):540-551. PubMed ID: 27546298
[TBL] [Abstract][Full Text] [Related]
2. Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review.
Beaupin LK; Bostrom B; Barth MJ; Franklin I; Jaeger R; Kamath P; Schreiber B; Bleyer A
Leuk Lymphoma; 2017 Apr; 58(4):766-772. PubMed ID: 27643446
[TBL] [Abstract][Full Text] [Related]
3. The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
Alrazzak M; Beaupin LK; Kinyoun P; Barth M
J Pediatr Hematol Oncol; 2016 Jan; 38(1):e16-20. PubMed ID: 26558809
[TBL] [Abstract][Full Text] [Related]
4. Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
Albertsen BK; Harila-Saari A; Jahnukainen K; Lähteenmäki P; Riikonen P; Möttönen M; Lausen B
Leuk Lymphoma; 2019 Jun; 60(6):1469-1475. PubMed ID: 30632847
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
Browne EK; Moore C; Sykes A; Lu Z; Jeha S; Mandrell BN
J Pediatr Oncol Nurs; 2018; 35(2):103-109. PubMed ID: 29161979
[TBL] [Abstract][Full Text] [Related]
6. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.
Hijiya N; van der Sluis IM
Leuk Lymphoma; 2016; 57(4):748-57. PubMed ID: 26457414
[TBL] [Abstract][Full Text] [Related]
7. Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia.
Asselin B
Future Oncol; 2016 Jul; 12(13):1609-21. PubMed ID: 27086555
[TBL] [Abstract][Full Text] [Related]
8. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
9. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
10. Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.
Shinnick SE; Browning ML; Koontz SE
J Pediatr Oncol Nurs; 2013; 30(2):63-77. PubMed ID: 23380527
[TBL] [Abstract][Full Text] [Related]
11. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.
Petersen WC; Clark D; Senn SL; Cash WT; Gillespie SE; McCracken CE; Keller FG; Lew G
Pediatr Hematol Oncol; 2014 May; 31(4):311-7. PubMed ID: 24498943
[TBL] [Abstract][Full Text] [Related]
12. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
Burke MJ; Zalewska-Szewczyk B
Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
[TBL] [Abstract][Full Text] [Related]
13. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
Larson RA; Fretzin MH; Dodge RK; Schiffer CA
Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia.
Rajić V; Debeljak M; Goričar K; Jazbec J
Leuk Lymphoma; 2015; 56(11):3103-8. PubMed ID: 25697915
[TBL] [Abstract][Full Text] [Related]
15. Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management.
Sandley M; Angus J
Leuk Lymphoma; 2023 Apr; 64(4):776-787. PubMed ID: 36781296
[TBL] [Abstract][Full Text] [Related]
16. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring.
Asselin B; Rizzari C
Leuk Lymphoma; 2015; 56(8):2273-80. PubMed ID: 25586605
[TBL] [Abstract][Full Text] [Related]
17. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.
Silverman LB; Supko JG; Stevenson KE; Woodward C; Vrooman LM; Neuberg DS; Asselin BL; Athale UH; Clavell L; Cole PD; Kelly KM; Laverdière C; Michon B; Schorin M; Schwartz CL; O'Brien JE; Cohen HJ; Sallan SE
Blood; 2010 Feb; 115(7):1351-3. PubMed ID: 20007809
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
19. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.
van der Sluis IM; Vrooman LM; Pieters R; Baruchel A; Escherich G; Goulden N; Mondelaers V; Sanchez de Toledo J; Rizzari C; Silverman LB; Whitlock JA
Haematologica; 2016 Mar; 101(3):279-85. PubMed ID: 26928249
[TBL] [Abstract][Full Text] [Related]
20. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH
Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]